Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
January 11, 2021Targovax to present at the H.C. Wainwright Virtual BioConnect 2021 Conference
-
January 6, 2021Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore
-
December 23, 2020Targovax ASA issues options to employees
-
December 15, 2020Targovax ASA: Save the date – Capital Markets Day 2021
Third quarter 2020
Targovax ASA (OSE: TRVX) announced its third quarter results 2020 on Thursday 5 November 2020.